Assessment of Complete Pathologic Response After Neoadjuvant Chemotherapy for Breast Cancer
Conditions: TN ER-/PR-/HER2- Breast Cancer; Triple Negative Breast Cancer; HER2-positive Breast Cancer; ERany/PRany/HER2+ Breast Cancer Intervention: Radiation: Standard Trimodality Breast Imaging Sponsor: Masonic Cancer Center, University of Minnesota Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | HER2 | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy | Research